Sunitinib malate (Sutent)
(Pfizer) Bioavailability not affected by food;
after oral dosing, Cmax observed 6-12 h (Tmax)
Vd= 2230 L
(substrate for ABCB1)
(184) Metabolized mainly by CYP3A4 50 mg orally once daily (4 weeks on, 2 weeks off); 37.5 mg orally (continuous daily dosing);
95% binding for sunitinib, 90% binding for sunitinib’s primary metabolite (HSA) Dyspnea and cough have been reported in association with sunitinib treatment (229);
there are no reports of sunitinib treatment-induced pneumonitis.